Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN 0302).

Trial Profile

Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN 0302).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Denileukin diftitox (Primary) ; Etanercept (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Pentostatin (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2011 Actual initiation date changed from Sep 2005 to Aug 2005 as reported by ClinicalTrials.gov (NCT00474149).
    • 16 May 2011 Actual initiation date changed from Sep 2005 to Aug 2005 as reported by ClinicalTrials.gov (NCT00474149).
    • 16 May 2011 Actual initiation date changed from Sep 2005 to Aug 2005 as reported by ClinicalTrials.gov (NCT00474149).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top